Mylan Receives Approval for Biosimilar in India; Reaches Settlement with Teva on Copaxone
Mylan and the Indian biopharmaceutical company Biocon receive approval for a biosimilar version of trastuzumab in India. Also, Mylan and Teva reach settlement on Copaxone in the EU.
The generic-drug/specialty pharmaceutical company Mylan and the Indian biopharmaceutical company Biocon have received approval for a biosimilar version of trastuzumab in India. The product is a biosimilar to Roche's Herceptin, indicated for the treatment of HER2 overexpressing breast cancer. Mylan intends to market its trastuzumab product under the trade name Hertraz.
Trastuzumab is one of five biologic products Mylan is developing in partnership with Biocon. Mylan has exclusive commercialization rights for biosimilar trastuzumab in the United States, Canada, Japan, Australia, New Zealand, and countries in the European Union and European Free Trade Association and co-exclusive commercialization rights with Biocon for the product in India. Mylan expects to launch trastuzumab in India early in 2014.
In other news, Mylan reports that it and Teva Pharmaceutical Industries have agreed to settle and dismiss pending patent litigation involving Teva's e multiple-sclerosis drug Copaxone (glatiramer acetate) in the United Kingdom, the Netherlands, and France relating to noninfringement and the validity of European Patent 0,762,888, which expires in May 2015. The terms of the settlement are confidential.
Source:
Mylan
and
Teva Pharmaceutical Industries
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
